Pricing Log in Create free account
Saturday 17 October 2026 Export VRTX’s income statement to Excel — free account

Vertex Pharmaceuticals Incorporated

VRTX Healthcare Biotechnology

Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024. In the quarter to June 2026, revenue grew 12.5%, EPS grew 7.96% and free cash flow grew 9.25%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years.

499.39 9.36 −1.84%
Market cap
$129.0B
P/E
28.8×
Fwd P/E
25.5×
Dividend yield
—
F-score
8/9
Altman Z
12.06
Beneish M
−2.17
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Vertex Pharmaceuticals Incorporated (VRTX) EV/Sales

Alert me on EV/Sales

As of 16 October 2026, Vertex Pharmaceuticals Incorporated (VRTX) trades at a EV/Sales of 9.5×. Over the past ten years it has ranged from 5.5× (October 2021) to 53.8× (August 2015); the current reading is higher than 36% of that period. That is in line with the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 9.1× 2.65%
FY2024 8.9× (7.81%)
FY2023 9.7× 36.52%
FY2022 7.1× 7.47%
FY2021 6.6× (26.48%)
FY2020 9.0× (29.96%)
FY2019 12.8× (2.20%)
FY2018 13.1× (11.68%)
FY2017 14.8× 42.69%
FY2016 10.4× (64.36%)

Quarterly newest first

Period EV/Sales Change
Jun 2026 9.4× 7.94%
Mar 2026 8.7× (4.55%)
Dec 2025 9.1× 13.75%
Sep 2025 8.0× (15.26%)
42 more quarters

Against its own ten years

Low 5.5× High 53.8×
Ten-year median 11.3×
Current reading's percentile 39

EV/Sales against peers

Company EV/Sales
REGN Regeneron Pharmaceuticals, Inc. compare 4.9×
ALNY Alnylam Pharmaceuticals, Inc. compare 6.0×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 6.1×
ARGX argenex SE compare 8.9×
VRTX Vertex Pharmaceuticals Incorporated 9.5×
RPRX Royalty Pharma PLC compare 14.0×
MRNA Moderna, Inc. compare 36.9×
RVMD Revolution Medicines, Inc. compare 1,287×
ROIV Roivant Sciences Ltd. compare 2,742×
Biotechnology industry median 9.2×
Healthcare sector median 3.4×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on VRTX